A5008433221- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Epigenetics and DNA Methylation
- Gastric Cancer Management and Outcomes
- Nutrition and Health in Aging
- Gallbladder and Bile Duct Disorders
- Cancer Immunotherapy and Biomarkers
- Adrenal and Paraganglionic Tumors
- Frailty in Older Adults
- Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Chromatin Remodeling and Cancer
- Liver Disease Diagnosis and Treatment
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- CAR-T cell therapy research
- Metabolism, Diabetes, and Cancer
- Advanced Causal Inference Techniques
- Privacy-Preserving Technologies in Data
University Hospital Heidelberg
2016-2025
Heidelberg University
2016-2025
Medical University of Vienna
2021-2024
Yahoo (United Kingdom)
2024
Massachusetts General Hospital
2018-2023
Harvard University
2018-2023
Chirurgische Universitätsklinik Heidelberg
2021
Boston University
2020
University of Göttingen
2016
Universitätsmedizin Göttingen
2016
To assess the relevance of resection margin status for survival outcome after and adjuvant therapy pancreatic cancer.The definitions R0 R1 cancer are controversial. The strict definition requiring a 1 mm tumor-free is not commonly accepted. Reported R0/R1 rates associated highly heterogeneous.A standardized protocol with rigorous assessment circumferential margins free were introduced into clinical routine in 2005. From prospective database, patients undergoing pancreatoduodenectomy...
To determine the prognostic value of PLN and LNR based on a large series with standardized lymphadenectomy pathological workup.Lymph node (LN) involvement is major factor in pancreatic adenocarcinoma. However, distinction N0/N1 not sufficient to accurately predict prognosis. improve accuracy N1 tumors, different LN parameters have been tested. Previous studies were variable numbers examined lymph nodes (ELN) came inconsistent conclusions as number positive (PLN) ratio (LNR).811 patients who...
To evaluate the impact of clinical and pathological parameters, including resection margin (R) status, on survival in patients undergoing pancreatic surgery after neoadjuvant treatment for initially unresectable ductal adenocarcinoma (PDAC).Prognostic factors are well documented with resectable PDAC, but have not been described detail PDAC therapy.Prospectively collected data consecutive cancer treated by were analyzed. The R status was categorized as R0 (tumor-free >1 mm), R1 ≤1 mm direct...
The definition of resection margin (R) status in pancreatic cancer is under debate. Although a at least 1 mm an independent predictor survival after for head cancer, its relevance to body and tail cancers remains unclear. This study aimed validate R based on 1-mm tumour-free as prognostic factor resected adenocarcinoma involving the tail.Patients who underwent distal or total pancreatectomy adenocarcinomas between January 2006 December 2014 were identified from prospective database....
To determine actual five-year survival (5YS) rates associated with a strategy of upfront surgery and adjuvant therapy in pancreatic ductal adenocarcinoma (PDAC).The rate 5YS PDAC remains controversial. Available data is restricted to cohorts acquired over several decades series resection after patient selection by neoadjuvant therapy.All patients undergoing for resectable borderline-resectable from 10/2001 12/2011 were identified prospective database. Actual overall was assessed follow-up at...
In the past decade, use of neoadjuvant therapy (NAT) has increased for patients with borderline and locally advanced pancreatic ductal adenocarcinoma (PDAC). Data on fistula related overall survival (OS) in this setting are limited.To compare postoperative complications undergoing either upfront resection or pancreatectomy following NAT, focusing clinically relevant (CR-POPF) potential associations OS.This retrospective cohort study was conducted data from who underwent PDAC at Massachusetts...
Purpose: The devastating prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDA) presents an urgent need for the development therapeutic strategies targeting disseminated tumor cells. Until now, T-cell therapy has been scarcely pursued in PDA, due to prevailing view that it represents a poorly immunogenic tumor. Experimental design: We systematically analyzed infiltrates biopsies from 127 PDA by means immunohistochemistry, flow cytometry, receptor (TCR) deep-sequencing...
To investigate the outcome of conversion surgery in patients with metastatic pancreatic cancer (mPDAC) and to identify who may benefit from this approach.The role mPDAC exceptional response chemotherapy remains unclear.Patients underwent surgical exploration for following between 2006 2019 were included. Data on demographics, oncologic treatment, pathology, postoperative outcomes analyzed. Univariate multivariate survival analyses performed.Some 173 received preoperative exploration....
Pancreatic acinar cell carcinoma (ACC) is an aggressive exocrine tumor with largely unknown biology. Here, to identify potential targets for personalized treatment, we perform integrative genome-wide and epigenome-wide analyses. The results show frequently aberrant DNA methylation, abundant chromosomal amplifications deletions, mutational signatures suggesting defective repair. In contrast pancreatic ductal adenocarcinoma, no recurrent point mutations are detected. suppressors ID3, ARID1A,...
Abstract Background An increasing body of evidence suggests that microbiota may promote progression pancreatic ductal adenocarcinoma (PDAC). It was hypothesized gammaproteobacteria (such as Klebsiella pneumoniae) influence survival in PDAC, and quinolone treatment attenuate this effect. Methods This a retrospective study patients from the Massachusetts General Hospital (USA) Ludwig-Maximilians-University (Germany) who underwent preoperative pancreatoduodenectomy for locally advanced or...
Significance Pancreatic ductal adenocarcinoma (PDA) is a highly lethal malignancy with no effective therapies. PDA aggressiveness partly stems from its ability to grow within uniquely dense stroma restricting nutrient access. This study demonstrates that clones survive chronic deprivation acquire reversible nongenetic adaptations allowing them switch between metabolic states optimal for growth under nutrient-replete or nutrient-deprived conditions. One contributing factor this adaptation...
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor (CoGNET), previously called ampullary gangliocytic paragangliomas, is a rare entity, with only few reported cases in the literature. This multicentric retrospective cohort study of patients treated endoscopy or surgery for CoGNET. A literature review CoGNET was also performed. Fifteen were included, mostly female (n = 10) median age 50 years. Patients asymptomatic seven cases. Four pancreatoduodenectomy, four transduodenal...
To validate the prognostic value of PAncreatic NeoAdjuvant MAssachusetts (PANAMA)-score and to determine its predictive ability for survival benefit derived from adjuvant treatment in patients after resection pancreatic ductal adenocarcinoma (PDAC) following neoadjuvant FOLFIRINOX. The PANAMA-score was developed guide prognostication therapy PDAC. As this score focuses on risk residual disease resection, it might also be able select who therapy. This retrospective international multicenter...
Objective: We analyzed perioperative outcomes of patients undergoing pancreatectomy with portal vein resection for pancreatic cancer using temporary intraoperative mesoportal or mesocaval bypass. Summary Background Data: Pancreatectomy advanced long-segment involvement complete occlusion the venous axis and cavernous transformation represents a major technical challenge. To avoid bleeding as well to overcome severe bowel congestion ischemia due long clamping, bypass graft first approach has...
Intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic cancer is typically managed like intraepithelial neoplasia (PanIN)-derived cancer. However, in IPMN-derived cancer, the role of chemotherapy remains controversial, particularly neoadjuvant setting (NAT). To evaluate Patients with treated either upfront surgery (US) or NAT were identified from eight international centers (2000-2023). Clinicopathologic data compared. Date first treatment was used for Kaplan-Meier and log-rank...
A genome-wide association study (GWAS) suggested inherited genetic single-nucleotide polymorphisms (SNPs) affecting overall survival (OS) in advanced pancreatic cancer. To identify robust clinical biomarkers, we tested the strongest reported candidate loci an independent patient cohort, assessed cellular drug sensitivity, and evaluated molecular effects. This comprised 381 patients with histologically verified ductal adenocarcinoma treated gemcitabine-based chemotherapy. The primary outcome...